Skip to main content
letter
. 2020 May 7;106(2):630–634. doi: 10.3324/haematol.2019.236745

Figure 2.

Figure 2.

Top hits of the drug screening and validation of the most promising candidate drugs on primary NUP98-KDM5A+ and NUP98-NSD1- acute myeloid leukemia samples. (A) Heatmaps of the most effective hits from the drug library screens at 10 nM, 100 nM and 1,000 nM on primary samples from a case of NUP98-KDM5A+ acute myeloid leukemia (AML) and a case of NUP98-NSD1+ AML, ranked by difference in cell viability. Drugs occurring multiple times in the heatmap indicate that the drug was present in multiple screened drug libraries. (B-G) Dose-response curves of the selected candidate drugs on primary NUP98-KDM5A+ (n=2) and NUP98-NSD1+ (n=3) AML samples to the tubulin inhibitors vincristine (top) and fosbretabulin (bottom) (B), the PI3K inhibitor omipalisib (C), the MEK inhibitor trametinib (D), the BRD4 inhibitors OTX-015 (top) and ARV825 (bottom) (E), the CDK9 inhibitors dinaciclib (top) and CDKI-73 (bottom) (F), and the HSP90 inhibitor ganetespib (G). Data are based on a 4-day MTT assay and normalized to values in controls treated with dimethylsulfoxide.